Hytrin

Terazosin, the active ingredient in Hytrin, is an alpha‑1 adrenergic antagonist presented as an oral tablet for systemic use. It is indicated for the management of hypertension and for relieving urinary obstruction caused by benign prostatic hyperplasia in adult patients.

GNH USA supplies Hytrin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Terazosin is employed to treat conditions that involve vascular tone and prostatic smooth‑muscle tone.

- Hypertension: reduces systemic blood pressure by relaxing arterial smooth muscle. - Benign prostatic hyperplasia (BPH): eases urinary flow obstruction by relaxing prostate and bladder neck smooth muscle.

Terazosin may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially when standing quickly. - Headache: mild to moderate pain often occurring early in therapy. - Fatigue: feeling unusually tired or weak.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Syncope: sudden loss of consciousness due to low blood pressure. - Priapism: prolonged, painful erection requiring immediate medical attention.

When prescribing terazosin, several safety considerations should be observed.

- Blood pressure monitoring: check baseline and periodically during therapy. - Orthostatic hypotension risk: start at low dose and advise patient to rise slowly. - Renal impairment: adjust dose if severe renal dysfunction is present. - Concomitant use with PDE5 inhibitors: avoid due to additive hypotensive effect. - Pregnancy and lactation: category B; use only if benefit outweighs risk. - Store at ambient temperature: keep in original container, protect from moisture.

Terazosin can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Sildenafil and other PDE5 inhibitors: may cause profound hypotension. - Potassium‑sparing diuretics (e.g., spironolactone): additive blood‑pressure lowering effect. - Other antihypertensives (e.g., ACE inhibitors, beta‑blockers): risk of excessive blood pressure drop.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may increase terazosin plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce terazosin effectiveness. - NSAIDs: may blunt antihypertensive response.